Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Meaning, whether you lose weight through a change in your diet, a different medication, or bariatric surgery, there is a risk of losing bone density. However, in this particular study, taking weight loss drugs like Ozempic did seem to have a bigger impact on bone density than losing weight through other means.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.